Progression was a loss of complete hematologic response or MCyR while receiving the maximum dasatinib dose, conversion to accelerated or blast phase CML, no complete hematologic response after receiving the maximum dose with an increase in white blood cell count (previously defined 2 ), or a 30% or greater absolute increase in the number of Ph + metaphases. Major molecular response was assessed by realtime quantitative polymerase chain reaction (RQ-PCR). The RNA isolated from 2.5 mL of whole blood collected in PAXgene TM (Preanalytix, Hombrechticon, Switzerland) reagent was reverse transcribed into cDNA, followed by the RQ-PCR assay for the absolute quantitation of BCR-ABL transcripts. BCR-ABL/BCR ratios were calculated and converted to the International Scale.
3 A major molecular response was defined as a 3-log reduction of BCR-ABL transcripts in peripheral blood leukocytes in comparison to the standardized baseline which is equivalent to 0.1% on the international scale. 3, 4 Assessment of BCR-ABL mutations was performed at baseline and at the end of treatment; data on baseline mutations are provided in this report. Peripheral blood RNA was collected and reverse transcriptase-polymerase chain reaction (RT-PCR) performed to amplify the BCR-ABL fusion transcript. The BCR-ABL point mutations were then analyzed by direct sequencing.
Patients were randomized to oral dasatinib 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily. Dose modifications were permitted per protocol criteria for management of progression or toxicities.
2 Doses could be escalated for inadequate response (as previously defined 2 ) up to 140 mg once daily, 70 mg twice daily, 180 mg once daily, or 90 mg twice daily. Treatment interruptions or dose reductions were permitted for bleeding or hemorrhage (per protocol criteria), grade 2 or greater non-hematologic toxicity considered treatment-related, or grade 3 or more hematologic toxicity. Doses could be reduced to 80 mg daily in both once daily treatment groups and to 40 mg twice daily in both twice-daily groups. Dasatinib was continued until progression or unaccept- Haematologica. 2010; 95:232-240. doi:10.3324/haematol.2009.011452 Original Articles -Appendix able toxicity. In accordance with a protocol amendment in 2007, 33 patients had their dose regimens changed by investigators from a twice daily to once daily regimen for specified adverse event criteria (fluid retention or cytopenias).
Additional definitions
Primary imatinib resistance/suboptimal response in patients receiving imatinib doses of 400 mg/day or more was defined as: no reduction in white blood cell count after at least 4 weeks, no complete hematologic response after 3 months, no MCyR after 6 months, or no complete cytogenetic response (CCyR) after 12 months of therapy.
Acquired imatinib resistance was a loss of MCyR, loss of molecular response with at least 10% Ph + metaphases, MCyR with a new BCR-ABL mutation, or loss of a confirmed complete hematologic response.
Patients who could not tolerate imatinib 600 mg/day or more, but had not achieved a CCyR on 400 mg were classified as imatinib-resistant.
Imatinib intolerant patients were defined as those who had experienced at least a grade 3 adverse event considered at least possibly related to imatinib at doses of 400 mg/day or less and subsequently discontinued therapy. Dasatinib 100 mg QD 70 mg BID 140 mg QD 50 mg BID P value (n=165) (n=167) (n=163) (n=167) All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4 n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 100 (61) 29 (18) 120 (73) 39 (24) 120 (74) 35 (22) 124 (75) 44 (27) (14) 4 (2) 38 (23) 9 (5) 41 (25) 8 (5) 39 ( (25) 2 (1) 45 (27) 7 (4) 47 (29) 6 (4) 52 (31) 4 (2) − Headache 54 (33) 1 (1) 50 (30) 5 (3) 48 (29) 3 (2) 38 (23) 
